In two studies, ceftriaxone was associated with higher risk for treatment failure or death compared with antistaphylococcal penicillins or cefazolin.
Current guidelines recommend at least 14 days of intravenous antibiotic treatment for Staphylococcus aureus bacteremia (SAB). As methicillin-susceptible S. aureus (MSSA) strains are generally susceptible to ceftriaxone, this agent, with its once-daily dosing, appears attractive for outpatient parenteral treatment. However, previous reports have yielded conflicting results regarding its efficacy in this setting.
Yetmar et al. conducted a retrospective cohort study of 223 adults treated with at least 7 days of outpatient parenteral therapy for MSSA bacteremia at several Mayo Clinic sites from 2018 through 2019. Sources of infection included skin or soft tissue (37%) and venous catheters (15%); in 21% of patients, the infection source was unkno…
Reviewing Authors
DisclosuresEditorial BoardsConsilium Infectiorum by InfectoPharm, Infection
DisclosuresEditorial BoardsConsilium Infectiorum by InfectoPharm, Infection
DisclosuresConsultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi
Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.
RoyaltiesUpToDate
Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases
DisclosuresConsultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi
Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.
RoyaltiesUpToDate
Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases